PHASE 1 EVALUATION OF BINTRAFUSP ALFA (M7824), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF-β AND PD-L1, IN CERVICAL CANCER

被引：6

作者：

Allan, S. ^{[1
]}

Braiteh, F. ^{[2
]}

Calvo Aller, E. ^{[3
]}

Cervantes, A. ^{[4
]}

Edenfield, W. ^{[5
]}

Li, T. ^{[6
]}

Rasschaert, M. ^{[7
]}

Park-Simon, T-W ^{[8
]}

Longo, F. ^{[9
]}

Paz-Ares, L. ^{[10
]}

Spira, A. ^{[11
,12
]}

Strauss, J. ^{[13
]}

Ojalvo, L. S. ^{[14
]}

Helwig, C. ^{[15
]}

Dussault, I. ^{[16
]}

Gulley, J. L. ^{[17
]}

机构：

[1] Tasman Oncol Res Ltd, Southport, Qld, Australia

[2] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[3] Hosp Madrid Norte Sanchinarro, CIOCC, START Madrid, Madrid, Spain

[4] Univ Valencia, Biomed Res Inst INCLIVA, Valencia, Spain

[5] Greenville Hosp Syst Univ Med Ctr ITOR, Greenville, SC USA

[6] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA

[7] Univ Ziekenhuis Antwerpen, Edegem, Belgium

[8] Hannover Med Sch, Hannover, Germany

[9] Hosp Univ Ramon y Cajal, Inst Ramon y Cajal Invest Sanitaria IRICYS, CIBERONC, Madrid, Spain

[10] Hosp Univ 12 Octubre, Madrid, Spain

[11] Virginia Canc Specialists, Fairfax, VA USA

[12] US Oncol Res, The Woodlands, TX USA

[13] NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[14] EMD Serono Inc, Immunooncol, Billerica, MA USA

[15] Merck Healthcare KGaA, Darmstadt, Germany

[16] EMD Serono Inc, Billerica, MA USA

[17] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2019年 / 29卷

关键词：

D O I：

10.1136/ijgc-2019-ESGO.100

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P37

引用

页码：A72 / A73

页数：3